AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26044353 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid brace
Number of subjects: 193
Study 26044353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up brace
Number of subjects: 193
Study 23332236 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg etanercept plus methotrexate
Number of subjects: 604
Study 23332236 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg etanercept plus methotrexate
Number of subjects: 604
Study 23332236 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 604
Study 21099130 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) intervention
Number of subjects: 15534
Study 21099130 — intervention group
Group type: COMPARATOR
Intervention: Control group (low EPA concentration)
Number of subjects: 15534
Study 19468948 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplementation (1.3 g daily for 6 weeks)
Number of subjects: 0
Study 19468948 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0
Study 19468948 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplementation
Number of subjects: 0
Study 18041889 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 18041889 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept with TNF-alpha inhibitors
Number of subjects: 0
Study 15601972 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS System (experimental group)
Number of subjects: 32
Study 15601972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 11329526 — intervention group
Group type: COMPARATOR
Intervention: Provider-reported symptoms
Number of subjects: 1262
Study 11329526 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported symptoms
Number of subjects: 1262
Study 9602398 — intervention group
Group type: EXPERIMENTAL
Intervention: General health screening
Number of subjects: 3064
Study 9602398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3064
Study 8288663 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed wound drainage
Number of subjects: 415
Study 8288663 — intervention group
Group type: COMPARATOR
Intervention: No postoperative drainage
Number of subjects: 415
Study 2688978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2466
Study 4915361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine 16 mg thrice daily for 11 days
Number of subjects: 0
Study 4915361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30970159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-related health factors and general health characteristics
Number of subjects: 321
Study 30970159 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health and life satisfaction
Number of subjects: 321
Study 28268163 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Twitter intervention (using personal Twitter accounts of editorial board members and trainees)
Number of subjects: 428
Study 28268163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no social media engagement)
Number of subjects: 428
Study 28268163 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Twitter intervention (using only the Journal's @JACRJournal Twitter account)
Number of subjects: 428
Study 28268163 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Twitter intervention
Number of subjects: 428
Study 28268163 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Twitter intervention
Number of subjects: 428
Study 28268163 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 428
Study 25833983 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (60 g daily)
Number of subjects: 63
Study 25833983 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (60 g daily)
Number of subjects: 63
Study 25833983 — intervention group
Group type: COMPARATOR
Intervention: High or low MC-SFA content (63 g milk fat daily)
Number of subjects: 63
Study 23580608 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (quantity)
Number of subjects: 580
Study 23580608 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sexual partners
Number of subjects: 580
Study 23580608 — intervention group
Group type: COMPARATOR
Intervention: Unprotected sex events
Number of subjects: 580
Study 21502454 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound-probing protocol (WPP) with daily probing between staples
Number of subjects: 76
Study 21502454 — intervention group
Group type: COMPARATOR
Intervention: Control arm (loose wound closure with staples every 2 cm)
Number of subjects: 76
Study 21502454 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound-probing protocol (WPP)
Number of subjects: 76
Study 19254788 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (20 and 40 mg daily combined)
Number of subjects: 7492
Study 16270215 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 30
Study 16270215 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (CLMA)
Number of subjects: 30
Study 15311663 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal molar and weight amounts of sucrose, fructose, and glucose
Number of subjects: 0
Study 15311663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose, fructose, and glucose
Number of subjects: 0
Study 15311663 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal sugar molarities and weights
Number of subjects: 0
Study 15311663 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0
Study 11194528 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake adjusted for energy intake
Number of subjects: 54
Study 11194528 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A intake
Number of subjects: 54
Study 11194528 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake at lower energy intakes
Number of subjects: 54
Study 9270085 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril combined with hydrochlorothiazide (20/6 mg)
Number of subjects: 374
Study 9270085 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 374
Study 8116814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus DEC (400 micrograms/kg plus 1 mg/kg)
Number of subjects: 30
Study 8116814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus DEC (400 micrograms/kg plus 3 mg/kg)
Number of subjects: 30
Study 8116814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus DEC (400 micrograms/kg plus 6 mg/kg)
Number of subjects: 30
Study 8116814 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (6 mg/kg) alone
Number of subjects: 30
Study 8116814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (400 micrograms/kg) alone
Number of subjects: 30
Study 8116814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (100 micrograms/kg) alone
Number of subjects: 30
Study 8116814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin plus DEC
Number of subjects: 30
Study 2904883 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (240 mg)
Number of subjects: 12
Study 2904883 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (100 mg x day‐1)
Number of subjects: 12
Study 2904883 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30113928 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 49
Study 30113928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 49
Study 30113928 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (SSRI + CBT)
Number of subjects: 49
Study 30113928 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 49
Study 30113928 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment
Number of subjects: 49
Study 30113928 — intervention group
Group type: COMPARATOR
Intervention: SSRI monotherapy
Number of subjects: 49
Study 28806955 — intervention group
Group type: EXPERIMENTAL
Intervention: SI + Gist
Number of subjects: 163525
Study 28806955 — intervention group
Group type: COMPARATOR
Intervention: SI
Number of subjects: 163525
Study 26554490 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional Microphone (DM) in the Transmitter (Tx)
Number of subjects: 18
Study 26554490 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional Microphone (OM) in the Transmitter (Tx)
Number of subjects: 18
Study 22339289 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA pulpotomy (PMTA: n = 208)
Number of subjects: 413
Study 22339289 — intervention group
Group type: EXPERIMENTAL
Intervention: CEM pulpotomy (PCEM: n = 205)
Number of subjects: 413
Study 21969284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose injection (12.5% dextrose)
Number of subjects: 54
Study 21969284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injection (1% lidocaine solution)
Number of subjects: 54
Study 21969284 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study 18360019 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple blockade with 25 mg of spironolactone added to ACE-I (5 mg enalapril) and ARB (50 mg losartan)
Number of subjects: 32
Study 18360019 — intervention group
Group type: COMPARATOR
Intervention: Control group with 1 mg of trichlormethiazide or 20 mg of furosemide added to ACE-I and ARB
Number of subjects: 32
Study 18360019 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple blockade with 25 mg of spironolactone added to ACE-I and ARB
Number of subjects: 32
Study 17133499 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a and ribavirin (RBV)
Number of subjects: 1046
Study 14689753 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 178
Study 14689753 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 178
Study 14689753 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 178
Study 12516410 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 126
Study 12516410 — intervention group
Group type: COMPARATOR
Intervention: Conventional-medicine (placebo: glucose, vitamin C, KCl)
Number of subjects: 126
Study 9302399 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (170 mg t.d.s.)
Number of subjects: 6
Study 9302399 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg t.d.s.)
Number of subjects: 6
Study 9302399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both inhibitors in combination
Number of subjects: 6
Study 8475946 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg per day
Number of subjects: 50
Study 8475946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2427835 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200, 400, or 600 mg once daily)
Number of subjects: 66
Study 2427835 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (12.5, 25, or 37.5 mg once daily)
Number of subjects: 66
Study 2427835 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 66
Study 2427835 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 66
Study 31586241 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid plus loxoprofen (ZOL + LOX)
Number of subjects: 368
Study 31586241 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid alone (ZOL)
Number of subjects: 368
Study 31586241 — intervention group
Group type: EXPERIMENTAL
Intervention: Past bisphosphonate users
Number of subjects: 368
Study 29793629 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (50, 150, or 300 mg) given subcutaneously once every 3 months
Number of subjects: 10061
Study 29793629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study 27149500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative dexmedetomidine (PRD)
Number of subjects: 223
Study 27149500 — intervention group
Group type: COMPARATOR
Intervention: Propofol/remifentanil/saline (PRS)
Number of subjects: 223
Study 24574431 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline and 0.1% hyaluronic acid (7% HS‐HA)
Number of subjects: 39
Study 24574431 — intervention group
Group type: COMPARATOR
Intervention: 0.9 normal saline (NS)
Number of subjects: 39
Study 23548062 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% dimeticone liquid gel applied once for 15 minutes
Number of subjects: 90
Study 23548062 — intervention group
Group type: COMPARATOR
Intervention: 1% permethrin creme rinse applied for 10 minutes, repeated after 7 days
Number of subjects: 90
Study 21423028 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/d)
Number of subjects: 20
Study 21423028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18182188 — intervention group
Group type: COMPARATOR
Intervention: Laboratory and clinical remount procedures with occlusal corrections (Group LCRO)
Number of subjects: 30
Study 18182188 — intervention group
Group type: EXPERIMENTAL
Intervention: Only laboratory remount with occlusal corrections (Group LRO)
Number of subjects: 30
Study 18182188 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine procedures without remount corrections (Group OOC)
Number of subjects: 30
Study 16541858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture once daily
Number of subjects: 49
Study 16541858 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture twice each week
Number of subjects: 49
Study 14719212 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (200 mg per day for 2 weeks) with 3.0 g calcium lactate and 0.75 microg alphacalcidol
Number of subjects: 102
Study 14719212 — intervention group
Group type: COMPARATOR
Intervention: Control (3.0 g calcium lactate and 0.75 microg alphacalcidol)
Number of subjects: 102
Study 11272799 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and conventional therapy for four weeks
Number of subjects: 20
Study 11272799 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study 8857480 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-length participation in cardiac rehabilitation (CRP) for >1 year
Number of subjects: 50
Study 8857480 — intervention group
Group type: COMPARATOR
Intervention: Standard-length participation in cardiac rehabilitation (CRP) for 3 months
Number of subjects: 50
Study 1474179 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 28
Study 1474179 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 28
Study 1474179 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (Control)
Number of subjects: 28
Study 1474179 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 28
Study 6880227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day for 8 weeks
Number of subjects: 0
Study 6880227 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg at night after full-dose course
Number of subjects: 0
Study 6880227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (both dosages)
Number of subjects: 0
Study 29334322 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 110
Study 29334322 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF exon IV and p11 promoter methylation
Number of subjects: 110
Study 30107787 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally supported personalised home‐based exercise training program (VITA group)
Number of subjects: 240
Study 30107787 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally supported personalised home‐based exercise training program plus dietary protein counselling (VITA-Pro group)
Number of subjects: 240
Study 30107787 — intervention group
Group type: COMPARATOR
Intervention: Regular weekly exercise program (Control group)
Number of subjects: 240
Study 27806243 — intervention group
Group type: COMPARATOR
Intervention: zidovudine alone
Number of subjects: 3490
Study 27806243 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine-based ART
Number of subjects: 3490
Study 27806243 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir-based ART
Number of subjects: 3490
Study 24676931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg daily
Number of subjects: 57
Study 24676931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 21778035 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal Replacement (MR) with high soy protein content and low glycemic index (GI)
Number of subjects: 11
Study 21778035 — intervention group
Group type: COMPARATOR
Intervention: Standardized breakfast with high GI and low protein content
Number of subjects: 11
Study 20034615 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 45
Study 20034615 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 45
Study 20034615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17327539 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session group intervention based on proactive coping theory
Number of subjects: 158
Study 17327539 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 158
Study 17327539 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session group intervention
Number of subjects: 158
Study 15766835 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 5030
Study 15766835 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 5030
Study 12202968 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 15
Study 12202968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10440457 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol with Carbamazepine (CBZ)
Number of subjects: 27
Study 10440457 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol with Valproate (VPA)
Number of subjects: 27
Study 10440457 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 27
Study 7783110 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER (mean daily dose 11.2 mg)
Number of subjects: 118
Study 7783110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (mean daily dose 7.4 mg)
Number of subjects: 118
Study 7783110 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER
Number of subjects: 118
Study 7783110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 118
Study 1970266 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 (Visacor) 50 mg
Number of subjects: 10
Study 1970266 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 (Visacor) 100 mg
Number of subjects: 10
Study 1970266 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 (Visacor) 200 mg
Number of subjects: 10
Study 1970266 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 (Visacor) 300 mg
Number of subjects: 10
Study 1970266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6253100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine
Number of subjects: 15
Study 6253100 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 15
Study 6253100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine and Metoclopramide (combination)
Number of subjects: 15
Study 6253100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6253100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone and Metoclopramide (unrandomized pilot study)
Number of subjects: 15
Study 30898825 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management Smartphone app (My Journey 3) plus Treatment As Usual (TAU)
Number of subjects: 40
Study 30898825 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) only
Number of subjects: 40
Study 28917577 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (CH)
Number of subjects: 169
Study 28917577 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 169
Study 28917577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 169
Study 25816197 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of olmesartan and amlodipine
Number of subjects: 376
Study 22930216 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially absorbable polypropylene mesh (PA)
Number of subjects: 200
Study 22930216 — intervention group
Group type: COMPARATOR
Intervention: Conventional polypropylene mesh (PP)
Number of subjects: 200
Study 22930216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 200
Study 21849247 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional transarterial chemoembolization
Number of subjects: 67
Study 21849247 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB transarterial chemoembolization
Number of subjects: 67
Study 21849247 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 67
Study 19484832 — intervention group
Group type: EXPERIMENTAL
Intervention: Early iron supplementation (3-4 mg/kg/day orally from 2 weeks)
Number of subjects: 46
Study 19484832 — intervention group
Group type: COMPARATOR
Intervention: Control (no iron until 60 days)
Number of subjects: 46
Study 18755784 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Risk Appraisal for Older Persons (HRA-O)
Number of subjects: 2503
Study 18755784 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 2503
Study 16252379 — intervention group
Group type: EXPERIMENTAL
Intervention: Early psychiatric intervention (mental health screening and referral to psychogeriatric service)
Number of subjects: 106
Study 16252379 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 106
Study 11940751 — intervention group
Group type: EXPERIMENTAL
Intervention: Translaryngeal technique
Number of subjects: 100